nivolumab,ipilimumab
bms
['hcrn,gu16,260', 'hcrn,gu,16,260', 'nivolumab', 'nivo', 'renal,(-adrenal)', 'rcc,(-irccs),(-srcc),(-urcc)']
 david a. braun, md, phd of presents his abstract: determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (rcc) tumors from the hcrn gu16-260 
An independent nonprofit cancer research organization conducting multi-center investigator-initiated oncology studies since 1984.